+34 93 402 04 56 info@proteodesign.es

About ProteoDesign

About 2
About 3
About 1
ProteoDesign is a biotech spin-out from Princeton University focused on personalized immuno-oncology therapies. The company is built on the pioneering discovery of a novel proprietary protein engineering platform technology that enables the development of next-generation biologics. We are developing personalized cancer immunotherapies that specifically target immune cells to induce a native innate and adaptive immune response against the tumor.

Standing on the shoulders of giants

Our immuno-oncology approach stems from the seminal discovery of a novel protein engineering technology at Princeton University by co-founders Miquel Vila-Perelló and Prof. Tom W. Muir (Muir TW., PNAS 1998; Vila-Perelló M., JACS 2013). Pioneering research in immunology was conducted in collaboration with the laboratory of the late Prof. Ralph Steinman (2011 Nobel Prize in Physiology or Medicine) at The Rockefeller University. This collaborative work (Barbuto S., Nat. Chem. Biol. 2013) now continues through a research collaboration between ProteoDesign and Stanford University.

Platform for next-generation biologics

In addition to our in house development of proprietary programs in immunotherappy, ProteoDesign has partnered its platform to enable the development of next-generation biologics. We have established two research collaborations with Amgen (Frutos S., Org. Biomol. Chem. 2016) and an undisclosed top 10 pharma, among others. We continue to selectively pursue alliances with potential partners interested in developing the next-generation biologics.